Thermo Fisher Scientific (TMO) — Q3 2026 Earnings Preview
Key Preview Takeaways
| Factor | Details & Signals to Watch |
|---|---|
| Revenue Growth | Consensus: $11,949M (+9% YoY). Guidance: $47,400M–$48,100M for FY26 (6–8% YoY). Q2 organic growth +5%. |
| Organic Revenue Growth | Raised to ~4% for FY26 (upper end of 3–4% range). Q2 organic +5%, Q1 organic +1%. Q3 guide: expect ~4%. |
| EPS | Consensus: $5.03 (GAAP). Guidance: $24.93–$25.33 (Adj. EPS, FY26, +9–11% YoY). Q2 Adj. EPS: $6.03 (+13%). |
| Operating Margin | Q2: 22.8% (+90 bps YoY). FY26 guidance: 80 bps expansion. |
| Segment Trends | Pharma/biotech: mid-single-digit growth; Bioproduction, clinical research, and channel strong. |
| End Market Recovery | Academic/gov returned to low single-digit growth in Q2; China returned to low single-digit growth. |
| Acquisition Impact | Clario and Solventum filtration performing well; $1.6B revenue, $0.32 EPS expected FY26. |
| Guidance Watch | Management expects to deliver at upper end of organic growth range; orders running ahead of revenue. |
| Comparables | Q3 2025 revenue: $11,115M (+5% YoY then); Q3 2026 consensus: $11,949M (+7.5% YoY). |
Recent Results and Forward Estimates
Quarterly Financials — Actuals and Consensus
| Quarter | Revenue ($M) | YoY Growth | Gross Margin (%) | EBITDA ($M) | Net Income ($M) | GAAP EPS | Adj. EPS | Notes |
|---|---|---|---|---|---|---|---|---|
| Q2 2026 | 11,700 | +10% | 41.5 | 2,898 | 2,128 | 4.44 | 6.03 | Actual |
| Q1 2026 | 11,010 | +6% | 40.8 | 2,400 | 1,952 | 4.43 | 5.44 | Actual |
| Q4 2025 | 12,210 | +7% | 41.8 | 2,880 | 2,432 | 5.21 | 6.57 | Actual |
| Q3 2025 | 11,115 | +5% | 41.9 | 2,590 | 2,077 | 4.27 | 5.79 | Actual |
| Q3 2026E | 11,949 | +7.5% | 42.3 | 3,183 | 2,376 | 5.03 | Consensus estimate |
*Consensus figures are not actuals.
Full-Year Financials — Actuals and Guidance
| Fiscal Year | Revenue ($M) | YoY Growth | Gross Margin (%) | EBITDA ($M) | Net Income ($M) | GAAP EPS | Adj. EPS | Guidance/Consensus |
|---|---|---|---|---|---|---|---|---|
| 2026E | 47,872 | +8% | 41.7 | 12,490 | 9,343 | 20.12 | 24.93–25.33 | Guidance/Consensus |
| 2025 | 44,556 | +4% | 41.7 | 11,190 | 8,596 | 17.86 | 22.87 | Actual |
| 2024 | 42,799 | 42.0 | 10,785 | 8,310 | 16.28 | Actual |
Segment and End Market Performance — Q2 2026
| Segment / End Market | Q2 2026 Growth | Commentary |
|---|---|---|
| Pharma & Biotech | Mid-single digits | Broad-based; bioproduction, clinical research, and channel all strong. |
| Academic & Government | Low single digits | Returned to growth; chromatography/mass spec launches drove adoption. |
| Industrial & Applied | Mid-single digits | Electron microscopy, chemical analysis, and channel strong; semis and safety/security up. |
| Diagnostics & Health Care | Mid-single digits | Healthcare market channel and immunodiagnostics led growth. |
| China | Low single digits | Returned to growth; pharma/biotech and industrial/applied strong, academic/gov muted. |
Guidance Summary — As of Q2 2026
| Metric | FY26 Guidance (as of Q2) | Prior Guidance (Q1) | Notes |
|---|---|---|---|
| Revenue ($M) | 47,400 – 48,100 | 47,300 – 48,100 | Raised after Q2 beat; includes $200M FX tailwind |
| Organic Revenue Growth | ~4% (upper end of 3–4% range) | 3–4% | Now expect to deliver at upper end |
| Adj. EPS | $24.93 – $25.33 | $24.64 – $25.12 | Raised $0.25 at midpoint |
| Operating Margin | +80 bps YoY expansion | +70 bps | Includes 30 bps headwind from tariffs/FX |
| Acquisitions Impact | $1.6B revenue, $0.32 EPS | $0.32 EPS | Clario, Solventum filtration/separation |
| Microbiology Divest. | -$200M revenue, -$0.05 EPS | Expected Q3 close | |
| Free Cash Flow | $6.9B – $7.4B | $6.9B – $7.4B | No change |
| Share Buybacks | $4B (completed) | $3B (completed in Jan) | $1B in Q2 from microbiology divestiture proceeds |
| Diluted Shares | 370M – 373M | 370M – 375M |
What to Watch This Quarter
- Organic Revenue Growth: Management expects to deliver at the upper end of the 3–4% range for FY26, with Q2 organic growth at +5%. Q3 is expected to be similar to Q2, so a print above 4% would be a positive signal.
- Pharma/Biotech Momentum: This segment (~60% of revenue) continues to strengthen, with broad-based growth and improving biotech spend. Watch for continued mid-single-digit or better growth and commentary on pipeline/funding.
- Bioproduction and Clinical Research: Both are outperforming peers and driving share gains. Look for continued strong growth and any signals of further acceleration or competitive wins.
- Academic/Government Recovery: Q2 saw a return to growth, especially in the US and Europe. Sustained improvement here would support the higher end of guidance.
- China: Returned to growth in Q2, driven by pharma/biotech and industrial/applied. Any further acceleration or commentary on sustainability will be key.
- Clario and Solventum Integration: Both acquisitions are exceeding expectations. Watch for updates on synergy realization, revenue contribution, and margin impact.
- Operating Margin Expansion: Q2 saw +90 bps YoY; guidance for FY26 is +80 bps. Continued productivity and cost control are expected to drive this.
- Order Trends: Management notes orders are running ahead of revenue, supporting confidence in the back half and into 2027.
- Capital Deployment: $4B buybacks YTD, microbiology divestiture completed in Q3. Any new M&A or capital allocation commentary will be relevant.
Year-over-Year Comparable
- Q3 2025 Actuals: Revenue $11,115M (+5% YoY), Adj. EPS $5.79 (+10% YoY), organic revenue growth +3%.
- Q3 2026 Consensus: Revenue $11,949M (+7.5% YoY), GAAP EPS $5.03.
- Comparison: Q3 2026 faces a moderately tougher comp than Q3 2025, but management expects stronger organic growth and margin expansion, supported by improved end markets and acquisition contributions.
Management Tone and Intra-Quarter Commentary
- Momentum: "Customer activity across our end markets continued to strengthen." (Q2 call)
- Pharma/Biotech: "Very encouraging to see the continued progression... definitely good momentum continues in pharma, but also biotech, clearly, we saw spending pick up."
- Guidance Philosophy: "We feel very good about the 4% outlook for the second half of the year... orders running ahead of revenue, so that bodes well for the future."
- Acquisitions: "Clario had a very good quarter... first full quarter of ownership was very strong... funnel of revenue synergies is building nicely."
- Academic/Gov: "Nice to have a positive quarter... funding flow is improving... slow stabilization of that end market."
- China: "Returned to growth... came away more bullish... believe that over time, it can return to be at least growing at the company average, if not better."
Summary and Conclusions
- Thermo Fisher enters Q3 2026 earnings with strong momentum, having raised full-year guidance after a clean Q2 beat.
- Organic revenue growth is expected at the upper end of the 3–4% range, with Q2 at +5% and Q3 expected to be similar.
- Pharma/biotech, bioproduction, and clinical research are key drivers, with academic/government and China showing signs of recovery.
- Acquisitions (Clario, Solventum) are exceeding expectations and contributing to both top and bottom line.
- Operating margin expansion and strong order trends support confidence in delivering on raised guidance.
- Year-over-year comparables are moderately tougher, but the setup is favorable given improved end markets and execution.
- Key factors to watch: sustained organic growth, segment momentum, margin expansion, and continued integration of acquisitions.
Thermo Fisher is well positioned for another strong quarter, with upside risk if end market recoveries and acquisition synergies continue to outpace expectations.
